Bill · H.R. 5160· House(119-HR-5160)
Stem Cell Therapeutic and Research Reauthorization Act of 2025
- Introduced
- 9/4/2025
- Last activity
- 7/21/2026 — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- Sponsored by
- Christopher Smith
- Cosponsors
- - 10 - 11
- Introduced
- Passed House
- Awaiting Senate
- On Senate calendar
What this bill would do
This Act, known as the Stem Cell Therapeutic and Research Reauthorization Act of 2025, serves to reauthorize the Stem Cell Therapeutic and Research Act of 2005. It updates the funding for the C.W. Bill Young Cell Transplantation Program by setting appropriations for fiscal years 2027 through 2031. The bill also modifies how the National Cord Blood Inventory is managed and defined. It changes the specific requirement for the number of cord blood units to a supply level determined by the Secretary. Additionally, it provides the Secretary with authority to transfer units to ensure continued availability and manage the inventory's size and composition.
Yes· 3 of 4
Does this make health care easier to get in general?+5
The bill enhances the management and availability of high-quality cord blood units through updated inventory protocols and increased funding.
Does this put more money into medical research?+4
The bill increases funding for the cell transplantation program and directs the Secretary to use current scientific and clinical information for inventory management.
Would children be better off under this?+4
Increased cord blood inventory management and funding can improve medical options available for children requiring cell transplants.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Funding for Cell Transplantation: The bill updates the C.W. Bill Young Cell Transplantation Program to include appropriations of $33,009,000 for each of fiscal years 2027 through 2031 (Section 2).
-
Ensuring Continued Availability of Cord Blood: The Secretary is granted authority to transfer cord blood units to another qualified bank or entity if a bank is no longer operational or fails to meet requirements, which helps ensure the continued availability of high-quality units (Section 3(b)(5)).
-
Scientific and Clinical Optimization: The Secretary is directed to manage the National Cord Blood Inventory to maximize clinical utility and ensure genetic diversity (Section 3(d)(1)).
-
Adaptability to Scientific Progress: The Secretary is required to consider current scientific and clinical information when entering into or extending contracts to maximize the availability of high-quality units (Section 3(c)).
Potential Negative Impacts for People
-
Removal of Specific Quantity Minimums: The bill removes the specific requirement of "at least 150,000 new units of high-quality cord blood," replacing it with a supply level that is determined solely by the Secretary (Section 3(a)).
-
Increased Discretionary Power for the Secretary: The Secretary is given broad authority to make determinations regarding the continued storage of units and can prioritize the collection or disposition of units based on various scientific, clinical, or operational considerations (Section 3(d)(1)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Improves Healthcare Access+5Increases Research Funding+4
- Demographic And Interest Groups
- Good For Children+4
- Education And Technology
- Increases Scientific Research Funding+3
- 7/21/2026
- Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- 7/20/2026
- Motion to reconsider laid on the table Agreed to without objection.
- Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
- Considered under suspension of the rules. (consideration: CR H4642-4643)
- Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- 7/2/2026
- Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- Placed on the Union Calendar, Calendar No. 629.
- 5/29/2026
- 2 Cosponsors added.
- 5/21/2026
- Committee Consideration and Mark-up Session Held
- Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
- 2 Cosponsors added.
- 5/13/2026
- Subcommittee Consideration and Mark-up Session Held
- Forwarded by Subcommittee to Full Committee by Voice Vote.
- 4/30/2026
- 2 Cosponsors added.
- 4/27/2026
- 2 Cosponsors added.
- 4/2/2026
- 4 Cosponsors added.
- 2/10/2026
- 2 Cosponsors added.
- 2/4/2026
- 2 Cosponsors added.
- 9/4/2025
- Referred to the House Committee on Energy and Commerce.
- Referred to the Subcommittee on Health.
- 5 Cosponsors added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Robert AderholtRepublican · Alabama
Cliff BentzRepublican · Oregon
Gus BilirakisRepublican · Florida
Nanette BarragánDemocrat · California
Kathy CastorDemocrat · Florida
Debbie DingellDemocrat · Michigan
Sharice DavidsDemocrat · Kansas
Brian FitzpatrickRepublican · Pennsylvania
Michelle FischbachRepublican · Minnesota
Brad FinstadRepublican · Minnesota
Josh GottheimerDemocrat · New Jersey
Andrew GarbarinoRepublican · New York
Michael LawlerRepublican · New York
Nicole MalliotakisRepublican · New York
Kweisi MfumeDemocrat · Maryland
Doris MatsuiDemocrat · California
Kelly MorrisonDemocrat · Minnesota
Eleanor NortonDemocrat · District of Columbia
Chellie PingreeDemocrat · Maine
Claudia TenneyRepublican · New York
Eugene VindmanDemocrat · Virginia